| Literature DB >> 26215252 |
Sara Fors1, Sofie Van Meervenne2, Janis Jeserevics3, Mindaugas Rakauskas4, Sigitas Cizinauskas5.
Abstract
Feline hippocampal and piriform lobe necrosis (FHN) has been reported from several countries worldwide and is considered an important aetiology for feline epileptic seizures. The aetiology of FHN remains unclear, however it is suspected that FHN might occur secondary to intense epileptic activity as described in humans and dogs although this has not yet been documented in cats. The purpose of our report is to describe the first cases of FHN in Finland diagnosed by magnetic resonance imaging (MRI) and histopathology. The two cases we describe had a well documented history of pre-existing seizures with normal brain MRI at the onset of cluster seizures but MRI done when the cats exhibited clinical deterioration secondary to severe seizure activity, revealed lesions in the hippocampus and piriform lobes typical of FHN. Our report confirms that feline hippocampus and piriform lobe necrosis does occur in the Finnish cat population and should therefore be considered as a differential diagnosis in cats with seizures. In addition, the presentation, clinical findings, results of MRI and/or histopathology shows that cats may develop FHN secondary to severe seizure activity.Entities:
Mesh:
Year: 2015 PMID: 26215252 PMCID: PMC4515920 DOI: 10.1186/s13028-015-0127-x
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Summary of selected material, methods and results not mentioned in the text for two cats with FHN
| Case 1 | Case 2 | |
|---|---|---|
| Ancillary diagnostics | Haematology and serum biochemistry profile normal, CSF normal | Haematology and serum biochemistry profile normal, EEGd-no epileptic activity |
| EEGd (2nd exam): duration 39 min 55 s; continuous short paroxysms and spikes at the C3 electrode | ||
| Emergency treatment | 2nd exam: medetomidineª 75 µg/kg | 1st exam: phenobarbitalb 10 + 4 + 4 mg/kg IV, diazepamc 0.5 mg/kg IV, medetomidinea 40 µg/kg intramuscular |
| IM, phenobarbitalb 10 mg/kg IV | 2nd exam: medetomidinea 30 µg/kg IM, diazepamc 0.5 mg/kg IV and phenobarbitalb 6 mg/kg IV | |
| At home treatment | Diazepam 0.6 mg/kg twice daily (BID) orally (PO) was started the day prior to referral | Phenobarbitalb 3 mg/kg BID PO prior to referral |
| Phenobarbitalb 1.9 mg/kg BID PO, increased to 3.8 mg/kg BID after 2 months |
EEG electroencephalography, IV intravenously, IM intramuscularly, PO per os, SID once daily, BID twice daily.
aDomitor vet, Orion Pharma Animal Health, Finland.
bFenemalRecip, Recip, Sweden; Barbivet®, Vetcare oy, Finland.
cStesolid® Novum, Actavis, Iceland.
dEEG performed using portable EBNeuro EEG equipment (Galileo Be Light Peripheral Configuration, EBNeuro, Firenze, Italy) and a method of standardized placement of EEG electrodes resembling the 10–20 international system for humans. A 14-channel reference montage (F7, F3, F4, F8, T3, C3, Cz, C4, T4, P3, Pz, P4, O1, O2; sensitivity, 10 µV/mm; time constant, 0.3 s; Hf, 70 Hz; notch filter inserted; reference: between the eyes on the ridge of the nose; ground: caudally to the external occipital protuberance) was used to record the EEG. Sixteen EEG needles (EEG needles, 30 gauge 15 mm monopolar stainless steel needle electrodes, BIONEN S.a.s., Firenze, Italy) were inserted as subdermal active, reference, and ground electrodes. Impedances did not exceed 5 Ω.
Summary of methods: anaesthesia, MRI sequences, imaging parameters and contrast media for two cats with FHN
| Case 1 | Case 2 | |
|---|---|---|
| Anaesthesia for MRI | Medetomidinea 75 µg/kg IM, propofolb IV isofluranec, O2 | Medetomidinea 30 µg/kg IM, propofolb IV isofluranec, O2 |
| MRI equipment and positioning | 0.2 T Vet-MR, Esaote S.p.A, Genoa, Italy) with the cat placed in sternal recumbency in a human knee coil | 0.2 T Vet-MR, Esaote S.p.A, Genoa, Italy) with the cat placed in sternal recumbency in a human knee coil |
| MRI sequences and imaging parameters and contrast media 1st examination | Pre-and post-contrast T1W trans (TR 460 ms, TE 18 ms, acquisition matrix 256 × 192, FOV 150 × 150 mm, slice thickness 4.5 mm, interslice gap 0.4 mm) | Pre-and post-contrast T1W trans (TR 750 ms, TE 26 ms, matrix 256 × 192, FOV 140 × 140 mm, slice thickness 3.5 mm, interslice gap 0.3 mm) |
| T2W trans and sag (TR 2,600 ms, TE 90 ms, acquisition matrix 192 × 192, FOV 130 × 130 mm, slice thickness 4.5 mm, interslice gap 0.4 mm) | T2W trans and sag (TR 3,000 ms, TE 90 ms, acquisition matrix 256 × 192, FOV 170 × 170 mm, slice thickness 3.5 mm, interslice gap 0.3 mm) | |
| Gadopentetd 0.1 mmol/kg IV | Gadopentetd 0.1 mmol/kg IV | |
| MRI sequences and imaging parameters and contrast media 2nd examination | Pre-contrast T1W trans (TR 750 ms, TE 26 ms, acquisition matrix 256 × 192, FOV 170 × 170 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | Pre- and post-contrast T1W trans (TR 800 ms, TE 26 ms, acquisition matrix 256 × 192, FOV 170 × 170 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) |
| Post-contrast T1W trans (TR 750 ms, TE 26 ms, acquisition matrix 256 × 192, FOV 170 × 170 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) dors (TR 600 ms, TE 26 ms, acquisition matrix 256 × 192, FOV 180 × 180 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | ||
| T2W trans and sag (TR 3,000 ms, TE 80 ms, acquisition matrix 256 × 192, FOV 180 × 180 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | T2W trans (TR 3,000 ms, TE 80 ms, acquisition matrix 192 × 192, FOV 180 × 180 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) and sag (TR 3,000 ms, TE 90 ms, acquisition matrix 192 × 192, FOV 170 × 170 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | |
| FLAIR trans and dors (TR 5,100 ms, TE 80 ms, acquisition matrix 288 × 192, FOV 220 × 220 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | FLAIR dors (TR 2,000 ms, TE 80 ms, acquisition matrix 256 × 192, FOV 200 × 200 mm, slice thickness 4.0 mm, interslice gap 0.4 mm) | |
| Gadopentetd 0.1 mmol/kg IV | Gadopentetd 0.1 mmol/kg IV |
MRI magnetic resonance, Trans transverse, Dors dorsal, Sag sagittal, FOV field of view, TR repetition time, TE echo time, IV intravenously, IM intramuscularly.
aDomitor vet, Orion Pharma Animal Health, Finland.
bRapinovet® vet, ScheringPlough Animal Health, Denmark.
cIsoFlo®vet, Orion Pharma Animal Health, Abbot Laboratories Ltd, Great Britain; Isofluran Baxter, Baxter, Sweden.
dMagnevist®, Bayer Schering Pharma, Finland.
Figure 1Case 1. a–c First MRI examination. A-T1W transversal, B-T2W transversal, C-T1W with contrast transversal magnetic resonance images. Normal appearance of the brain. Case 1. e–h Second MRI examination of the brain 32 months after epilepsy onset. E-T1W transversal, F-T2W transversal, G-T1W with contrast transversal, H-FLAIR transversal magnetic resonance images. Arrows indicate bilateral hyperintensity in the hippocampus in T2W + FLAIR and contrast enhancement in T1W + C. Magnetic resonance imaging findings consists of moderate to marked bilateral symmetric hyperintense lesions in T2W and FLAIR. Moderate to marked contrast enhancement is seen bilaterally in the hippocampus. d D-T2W sagittal magnetic resonance image with reference line located in rostral midbrain indicating where the transversal slices were obtained.
Figure 2Case 1. EEG at second presentation after onset of severe cluster seizures. Continuous epileptic activity can be seen, localized at the C3 electrode, manifesting as short paroxysms and spike activity.
Figure 3Case 1. Histopathology of the brain. Histology of different cornu ammonis segments (CA) 1 through 4. All areas show eosinophilic nerve cell necroses (white arrowheads). Presumable synaptic incrustation is occasionally seen (black arrowhead). CA4 is most severely affected and presents with severe cytodepletion next to actual nerve cell necroses. There further is an astrogliosis (AG) and microglial reaction (MG). Hil hilus of dentate gyrus, SGZ subgranular zone, G CL granular cell layer of dentate gyrus, HE, Prof.
Figure 4Case 2. a–c First MRI examination. A-T1W transversal, B-T2W transversal, C-T1W with contrast transversal magnetic resonance images. Normal appearance of the brain. Case 2. e–h Second MRI examination of the brain 4 days later. E-T1W transversal, F-T2W transversal, G-T1W with contrast transversal, H-FLAIR dorsal magnetic resonance images. Arrows indicate bilateral hyperintensity in the hippocampus in T2W + FLAIR and contrast enhancement in T1W + C. Magnetic resonance imaging findings consists of moderate bilateral symmetric T2-hyperintensity of the hippocampus. Marked bilateral hyperintensity of the hippocampus is seen in FLAIR and mild contrast enhancement bilaterally in the hippocampus in T1W post-contrast. d D-two T2W sagittal magnetic resonance images with one reference line located in rostral midbrain indicating where the transversal slices were obtained and one reference line showing the level where the dorsal FLAIR slice obtained.